Novavax, Inc. (NVAX)
After hours: 06:32PM EDT
| Previous close | 169.74 |
| Open | 170.00 |
| Bid | 161.72 x 1200 |
| Ask | 161.82 x 3200 |
| Day's range | 160.33 - 170.74 |
| 52-week range | 76.59 - 331.68 |
| Volume | 3,139,715 |
| Avg. volume | 5,084,993 |
| Market cap | 12.063B |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -13.84 |
| Earnings date | 08 Nov 2021 - 12 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 264.20 |
- Editor's pickYahoo Finance Video
NIH Director on FDA ‘being careful’ in clearing Moderna vaccine for kids 12-17
Dr. Francis Collins, Outgoing NIH Director, joins Yahoo Finance’s Anjalee Khemlani to discuss Covid-19 vaccine production, drug development research, and misinformation surrounding Covid-19 vaccines.
- Motley Fool
Why Shares of Moderna, Novavax, and Ocugen Are Falling Today
Shares of Moderna (NASDAQ: MRNA) are off by 3.4%; Novavax (NASDAQ: NVAX) is down 5.1%; and Ocugen's (NASDAQ: OCGN) stock is in the red by a jaw-dropping 13.3%, all as of 3:34 p.m. EDT Friday. The U.S. Food and Drug Administration (FDA) might delay the decision on Moderna's jab for adolescents due to safety issues, according to a report from the Wall Street Journal.
- Zacks
Novavax (NVAX) Lags in COVID Vaccine Race: Will It Gather Pace?
Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space. Let us see how the company is likely to perform going forward.
